Erik Harris Denali Therapeutics Inc. (DNLI) insider trading activity

DNLI Quotes by TradingView

Erik Harris is Director of Denali Therapeutics Inc.. Currently has a direct ownership of 17,052 shares of DNLI, which is worth approximately $351,441. The most recent transaction as insider was on May 31, 2024, when has been sold 5,967 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 17.1K
0% 3M change
53.83% 12M change
Total Value Held $351,441

Erik Harris Transaction History

Date Transaction Value Shares Traded Shares Held Form
May 31 2024
BUY
Grant, award, or other acquisition
-
5,967 Added 25.92%
17,052 Common Stock
Jun 01 2023
BUY
Grant, award, or other acquisition
-
4,216 Added 27.55%
11,085 Common Stock
Feb 03 2022
BUY
Grant, award, or other acquisition
-
6,869 Added 50.0%
6,869 Common Stock

Also insider at

RARE
Ultragenyx Pharmaceutical Inc. Healthcare
EVP & Chief Commercial Officer
INZY
Inozyme Pharma, Inc. Healthcare
EH

Erik Harris

Director
Novato, CA

Track Institutional and Insider Activities on DNLI

Follow Denali Therapeutics Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells DNLI shares.

Notify only if

Insider Trading

Get notified when an Denali Therapeutics Inc. insider buys or sells DNLI shares.

Notify only if

News

Receive news related to Denali Therapeutics Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on DNLI